Department of Applied Biochemistry
Jens Kurreck has not added Biography.
If you are Jens Kurreck and would like to personalize this page please email our Author Liaison for assistance.
Sequence requirements in the catalytic core of the "10-23" DNA enzyme.
The Journal of biological chemistry Oct, 2002 | Pubmed ID: 12192010
Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I.
The Journal of biological chemistry Mar, 2002 | Pubmed ID: 11751899
Design of antisense oligonucleotides stabilized by locked nucleic acids.
Nucleic acids research May, 2002 | Pubmed ID: 11972327
Antisense technologies. Improvement through novel chemical modifications.
European journal of biochemistry Apr, 2003 | Pubmed ID: 12694176
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.
Nucleic acids research Jun, 2003 | Pubmed ID: 12799446
RNA cleaving '10-23' DNAzymes with enhanced stability and activity.
Nucleic acids research Oct, 2003 | Pubmed ID: 14530446
Nucleic acids chemistry and biology.
Angewandte Chemie (International ed. in English) Nov, 2003 | Pubmed ID: 14618569
Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1.
Oligonucleotides , 2003 | Pubmed ID: 15000825
Expediting target identification and validation through RNAi.
Expert opinion on biological therapy Mar, 2004 | Pubmed ID: 15006736
Gaining target access for deoxyribozymes.
Journal of molecular biology May, 2004 | Pubmed ID: 15136038
Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Sep, 2004 | Pubmed ID: 15240563
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.
Nucleic acids research , 2004 | Pubmed ID: 15509871
Antisense and RNA interference approaches to target validation in pain research.
Current opinion in drug discovery & development Mar, 2004 | Pubmed ID: 15603251
Deletion analysis in the catalytic region of the 10-23 DNA enzyme.
FEBS letters Jan, 2005 | Pubmed ID: 15642375
Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs.
Journal of molecular biology Feb, 2005 | Pubmed ID: 15670596
Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.
Journal of molecular biology May, 2005 | Pubmed ID: 15843020
Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor.
Biological chemistry Sep, 2005 | Pubmed ID: 16164410
Comparative crystallization and preliminary X-ray diffraction studies of locked nucleic acid and RNA stems of a tenascin C-binding aptamer.
Acta crystallographica. Section F, Structural biology and crystallization communications Jul, 2006 | Pubmed ID: 16820689
Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
Biochemical and biophysical research communications Nov, 2006 | Pubmed ID: 16996476
RNA interference in pain research.
Journal of neurochemistry Oct, 2006 | Pubmed ID: 17029593
Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1.
Neurochemistry international Jan, 2007 | Pubmed ID: 17045702
siRNA efficiency: structure or sequence-that is the question.
Journal of biomedicine & biotechnology , 2006 | Pubmed ID: 17057371
Strand-specific silencing of a picornavirus by RNA interference: evidence for the superiority of plus-strand specific siRNAs.
Antiviral research Mar, 2007 | Pubmed ID: 17112603
Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice.
Molecular and cellular neurosciences Mar, 2008 | Pubmed ID: 18249134
Inhibition of translation in living eukaryotic cells by an RNA G-quadruplex motif.
RNA (New York, N.Y.) Jul, 2008 | Pubmed ID: 18515550
Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.
Journal of molecular medicine (Berlin, Germany) Sep, 2008 | Pubmed ID: 18548221
Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3.
FEBS letters Sep, 2008 | Pubmed ID: 18691577
Inhibition of picornaviruses by means of RNA interference.
Nucleic acids symposium series (2004) , 2008 | Pubmed ID: 18776254
ESF-EMBO symposium: antiviral applications of RNA interference.
Retrovirology Sep, 2008 | Pubmed ID: 18801178
RNA interference: from basic research to therapeutic applications.
Angewandte Chemie (International ed. in English) , 2009 | Pubmed ID: 19153977
Antiviral activity of highly potent siRNAs against echovirus 30 and its receptor.
Journal of virological methods May, 2009 | Pubmed ID: 19187792
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.
Circulation Mar, 2009 | Pubmed ID: 19237664
Locked nucleic acid aptamers.
Methods in molecular biology (Clifton, N.J.) , 2009 | Pubmed ID: 19377996
Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3.
Antiviral research Sep, 2009 | Pubmed ID: 19591879
RNA interference: Perspectives and caveats.
Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research Oct, 2005 | Pubmed ID: 19771205
Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3.
FEBS letters Feb, 2010 | Pubmed ID: 20005874
Proof of RNA interference in humans after systemic delivery of siRNAs.
Angewandte Chemie (International ed. in English) Aug, 2010 | Pubmed ID: 20648509
Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30.
Oligonucleotides Aug, 2010 | Pubmed ID: 20649454
Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions.
Antiviral research Oct, 2010 | Pubmed ID: 20708037
Design of small interfering RNAs for antiviral applications.
Methods in molecular biology (Clifton, N.J.) , 2011 | Pubmed ID: 21431692
Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.
Molecules (Basel, Switzerland) Oct, 2011 | Pubmed ID: 21989310
Application of Mutated miR-206 Target Sites Enables Skeletal Muscle-specific Silencing of Transgene Expression of Cardiotropic AAV9 Vectors.
Molecular therapy : the journal of the American Society of Gene Therapy Feb, 2013 | Pubmed ID: 23439498
Adenovirus vector-mediated RNA interference for the inhibition of human parvovirus B19 replication.
Virus research Sep, 2013 | Pubmed ID: 23770153
A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DNA as a standard.
Human gene therapy methods Dec, 2013 | Pubmed ID: 23987130
A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.
PloS one , 2014 | Pubmed ID: 24670775
Identification and characterization of RNA guanine-quadruplex binding proteins.
Nucleic acids research Jun, 2014 | Pubmed ID: 24771345
Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
The Journal of infectious diseases Feb, 2015 | Pubmed ID: 25193982
Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir.
Antiviral research Aug, 2015 | Pubmed ID: 26026665
Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells.
PloS one , 2015 | Pubmed ID: 26308932
Use of a three-dimensional humanized liver model for the study of viral gene vectors.
Journal of biotechnology Oct, 2015 | Pubmed ID: 26356676
Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
Future medicinal chemistry , 2015 | Pubmed ID: 26381598
Hepatitis E Virus Superinfection and Clinical Progression in Hepatitis B Patients.
EBioMedicine Dec, 2015 | Pubmed ID: 26844288
The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.
Journal of virology Jun, 2016 | Pubmed ID: 27030267
Biological antivirals for treatment of adenovirus infections.
Antiviral therapy Apr, 2016 | Pubmed ID: 27032991
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved